ISSN:0022-4790    

DOI:10.1002/jso.2930420502

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractThis presentation consists of two parts: 1) a brief account of the results of treating 94 patients with stage III (n = 24) and stage IV (n = 70) advanced head and neck cancer, primarily with two courses of preoperative adjuvant chemotherapy; and 2) an evaluation of 42 of the 94 patients consecutively treated by surgery by the senior author. It is our conclusion that preoperative chemotherapy using cisplatin, vincristine, and bleomycin can improve the compromised airway and deglutition without producing deleterious effects relative to surgical complications. Moreover, overall survival is promising and justifies continued study using organized protocols.

ISSN:0022-4790    

DOI:10.1002/jso.2930420503

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractThis paper briefly reviews the incidence of malignant pleural effusions (MPE) and the measures that have been used to treat this condition. The role of intracavitary bleomycin in controlling MPE, the doses used, and morbidity associated with its use are reviewed in depth with reference to multicenter studies that the author has coordinated as well as the published literature. The short‐ and long‐ term results reported when bleomycin was used alone or as compared with other agents are discussed. The author concludes that intracavitary bleomycin is an effective agent comparable to, if not more effective than, most agents used to prevent the recurrence of MPE after simple drainage procedures: it is safe and convenient to use; toxicity is low with minimal side effects and no myelosuppression. It can be safely administered to immunocomprised patients and those undergoing systemic chemother

ISSN:0022-4790    

DOI:10.1002/jso.2930420504

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractSince the work of Huggins and Hodges, hormonal therapy, i.e., orchiectomy or estrogens, has been the gold standard of treatment for patients with advanced adenocarcinoma of the prostate. Recently, many new drugs have been introduced in the hope of achieving a beneficial response as compared with hormonal therapy, while avoiding some of the adverse effects. Various newer agents are reviewed. It appears that while these agents may be attractive secondary to specific effects, they do not appear to offer any survival advantage over diethylstilbestrol or orchiectomy. Finally, the theory of total androgen blockade is reviewed. Institution of total blockade does not appear to offer a survival advantage over standard androgen blockade.

ISSN:0022-4790    

DOI:10.1002/jso.2930420505

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractThe current International Federation of Gynecology and Obstetrics (FIGO) staging system, independent prognostic factors, and review of the Gynecologic Oncology Group (GOG) studies in epithelial ovarian carcinoma are presented. With this background, approaches using cisplatin‐ based regimens in ovarian carcinoma trials are outlined. A short three‐ course cycle of cisplatin plus cyclophosphamide is currently being compared with intraperitoneal phosphorus 32 in high‐ risk stage I‐ II patients. In optimal stage III patients, cisplatin plus cyclophosphamide without doxorubicin in a recent GOG study was as effective as all three drugs. In suboptimal stage III patients, a current dose‐ intensity study is comparing 100 mg/m2cisplatin plus 1 g/m2cyclophosphamide for four courses to the previously studied eight courses of 50 mg/m2cisplatin and 500 mg/m2cyclophosphamide. Trials are also under way to determine the utility of intraperitoneal cisplatin in a phase III study of optimal stage III as first‐ line therapy and another study is active for second‐

ISSN:0022-4790    

DOI:10.1002/jso.2930420506

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractResults of several studies by the Lung Cancer Study Group have shown that postoperative adjuvant chemotherapy enhances survival following surgery for lung cancer. The 18‐ month disease‐ free survival almost doubled in one study using cyclophosphamide, doxorubicin, cisplatin (CAP) chemotherapy postoperatively. The recurrence rate remained significant, however. Patients with more advanced resectable disease seem to benefit most from postoperative chemotherapy. Results also suggest that CAP delays recurrences more effectively in patients with nonsquamous vs. squamous lung carcinoma. There has been considerable interest in the use of preoperative adjuvant therapy as well. Findings from studies of preoperative or induction therapy—either chemotherapy alone or in combination with radiation therapy—have shown high response rates and that patients with unresectable disease can be converted to technically resectable. Although preoperative therapy can cause difficulties with surgical dissection, surgical morbidity is acceptable. Preoperative chemotherapy and radiotherapy followed by surgical resection clearly eliminates local recurrence. Systemic recurrences remain a significant problem. The evidence, as yet, does not indicate that preoperative adjuvant therapy prolongs s

ISSN:0022-4790    

DOI:10.1002/jso.2930420507

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractEffective therapy for gastric cancer remains elusive, and thus surgeons, oncologists, and radiotherapists are continually confounded. Multiple attempts to improve survival in gastric cancer patients have failed, including extended lymphadenectomy (by American surgeons), single‐ or multipleagent chemotherapy, and combined‐ modality therapy (multiple‐ agent chemotherapy combined with radiation therapy). Such studies have been plagued by the high volume of inadequate antitumor responses or by lethal toxicity. At present, chemotherapy remains the best hope for effective adjuvant therapy, but new routes of drug delivery that will decrease systemic toxicity must be developed. Since gastric cancer recurs locoregionally and infrequently metastasizes to distant sites until very late in its course, theory suggests intraperitoneal (IP) chemotherapy applied to locoregional sites should decrease recurrence without significant systemic toxicity. Such treatments have been effective in other malignancies that commonly occur IP, such as ovarian cancer. Intracavitary chemotherapy protocols for gastric cancer are under development and will soon produce data on treatment efficacy. Such studies offer a theoretic basis for improved survival from gastric cancer; however, only well‐ controlled treatment trials will confirm if theory can be translated into clinical

ISSN:0022-4790    

DOI:10.1002/jso.2930420508

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

摘要:

AbstractThe cisplatin‐ based combination chemotherapy regimens of M‐ VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty‐ eight percent of the patients with metastatic disease had a complete (20%) or partial (28%) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M‐ VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is

ISSN:0022-4790    

DOI:10.1002/jso.2930420509

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY

ISSN:0022-4790    

DOI:10.1002/jso.2930420501

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1989

数据来源: WILEY